BioSpace News Archive

Onconova Therapeutics, Inc. announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa, associated with advanced/metastatic squamous cell carcinoma, will be presented in the Late Breaking News session at the EADV in Berlin, Germany.

Annovis Bio, Inc. today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without the addition of patients.

Avenge Bio, Inc. today announced participation in the upcoming investor conference.

Virion Therapeutics, LLC, and Ocean Biomedical, Inc. today announced they have entered into a joint venture to accelerate and expand Virion’s clinical-stage program and pipeline, with the goal of finding cures for patients with cancer and chronic infectious diseases.

OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time.

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, will present and host one-on-one meetings with investors during the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023, and on October 18, 2023 at the in-person BIO Investor Forum.

The Association for Molecular Pathology 2023 Annual Meeting & Expo will be held 14-18 November 2023 at the Salt Palace Convention Center in Salt Lake City, UT located in downtown Salt Lake City.

Centinel Spine®, LLC, (“the Company”) today announced that it will highlight the new prodisc Match-the-Disc™ cervical and lumbar TDR systems at the upcoming North American Spine Society (NASS) 38th Annual Meeting in Los Angeles, CA (October 18-21, 2023).

enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 12:00 PM ET.